Amgen, AstraZeneca score a PhIII psoriasis success with brodalumab

John Carroll After the markets closed Friday, Amgen and AstraZeneca announced that their top psoriasis contender, brodalumab, scored a win in Phase III, with a large majority of patients ...

AstraZeneca rushes immuno-oncology star into PhIII lung cancer study

John Carroll Anxious to fight off Pfizer’s $ 106 billion marriage proposal, AstraZeneca’s research team has rushed its high-profile immuno-oncology drug into a late-stage ...

Why pay $100B for AstraZeneca? Let Pfizer’s CEO count the reasons

Tracy Staton Pfizer considers itself a megamerger expert. And it's hoping to prove that with another megadeal–a $ 100 billion-or-so buyout of AstraZeneca. After last week's ...

Ignoring harsh lessons, Pfizer prepares to pounce on AstraZeneca

John Carroll The Financial Times reported Sunday evening that Pfizer may make a public declaration of its interest in buying out AstraZeneca within days after renewing an overture that ...

AstraZeneca shareholders pitch a fit about pay

Eric Palmer AstraZeneca CEO Pascal Soriot saw his pay fall last year along with the company's fortunes but that didn't keep large blocks of shareholders from displaying their ...

AstraZeneca joins stepped-up antibiotic R&D action with FOB Synthesis deal

Tracy Staton AstraZeneca notched an antibiotics research deal with a licensing/option set-up with FOB Synthesis, covering combinations of the two companies' experimental drugs. FiercePharma ...

AstraZeneca buys a CDK9 cancer drug portfolio

John Carroll AstraZeneca has swooped in to pick up a portfolio of new cancer therapy from Germany's Probiodrug. The pharma giant paid an undisclosed sum for the biotech's CDK9 ...

AstraZeneca, BMS pull Forxiga in Germany in snit over pricing

Eric Palmer AstraZeneca and Bristol-Myers Squibb look to be feeling good about the future of their diabetes drug Forxiga. The drugmakers have yanked the diabetes treatment from the ...

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

Tracy Staton When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there ...

AstraZeneca launches PhIII lung cancer study in late-stage rebuilding effort

John Carroll A decade after obtaining the rights to the cancer drug selumetinib from Array Biopharma, the hungry pharma giant AstraZeneca is moving the MEK inhibitor into a late-stage ...

AstraZeneca, Harvard partner to advance ‘Organs-on-Chips’ drug-testing tech

Emily Mullin AstraZeneca has teamed up with Harvard University's Wyss Institute for Biologically Inspired Engineering to use the institute's "Organs-on-Chips" technology–miniature ...

AstraZeneca, Amgen Crohn’s drug runs into PhII ‘logistical’ snafu

John Carroll One of the programs involved in AstraZeneca's $ 50 million bid to collaborate with Amgen on the development of a slate of biologics has run into a snafu of some sort. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS